Last update 22 Mar 2025

BI-1034020

Overview

Basic Info

Drug Type
Nanobody
Synonyms
BI 1034020
Target
APP
Action
inhibitors
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors)
Therapeutic Areas
Nervous System Diseases
Active Indication
Alzheimer Disease
Inactive Indication-
Originator Organization
Ablynx NVAblynx NV
Active Organization
Ablynx NVAblynx NV
Inactive Organization
Boehringer Ingelheim GmbHBoehringer Ingelheim GmbHBoehringer Ingelheim Pharmaceuticals, Inc.
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with BI-1034020
NCT01958060
/ TerminatedPhase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)
100 Clinical Results associated with BI-1034020
Login to view more data
100 Translational Medicine associated with BI-1034020
Login to view more data
100 Patents (Medical) associated with BI-1034020
Login to view more data
100 Deals associated with BI-1034020
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 1
Germany
Boehringer Ingelheim Pharmaceuticals, Inc.
-
Alzheimer DiseasePhase 1-
Ablynx NVAblynx NV
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01958060 (CTgov)
Phase 1
-
35
placebo+BI 1034020
(Placebo)
wxrrojwtzy = pncylwrkll mxxphswzmc (nxckevspem, ubmdokyzao - aozbviyqiu)
View more
-
30 Jul 2015
(BI 1034020 (5 mg/25 mL - iv))
wxrrojwtzy = neifmjpynk mxxphswzmc (nxckevspem, qtabinohbi - jjftqwcalw)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free